Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462568 | 0.89 | PPARD (0.61) | CYP3A4PPARDLPAR3LPAR1LPAR2 | |
| SCHEMBL11421377 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL575182 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11514808 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11267341 | 0.86 | CYP3A4 (0.50) | CYP3A4PPARDLPAR3LPAR1LPAR2 | |
| SCHEMBL11515024 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11040982 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11564266 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10832782 | 0.84 | CYP3A4 (0.64) | CYP3A4PPARDLPAR3LPAR1LPAR2 | |
| SCHEMBL4451725 | 0.83 | PPARD (0.48) | CYP3A4PPARDLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| US-7612148-B2 | Hydrogenation catalyst composition and method for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2009-11-03 | — | — | US | disclosed |
| US-20080146733-A1 | Hydrogenation catalyst composition and method for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2008-06-19 | — | — | US | disclosed |
| US-4250124-A | FIREPROOFING TEXTILES; REACTION OF AN HYDROXY-CONTAINING COMPOUND AND A 2-SUBSTITUTED-2-OXO-OXA-PHOSPHOLANE | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
| US-4244893-A | FIREPROOFING; FINISHES FOR TEXTILES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-13 | — | — | US | disclosed |
| US-4220610-A | Organic phosphorus compounds with 2-hydroxyalkyl-phosphonic acid groups | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-02 | — | — | US | disclosed |
| US-4163034-A | DECYCLIZATION, ESTERIFICATION; FIREPROOFING | HOECHST AG. (DE) | 1979-07-31 | — | — | US | disclosed |
| US-4096208-A | FIREPROOFING AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | CYP3A4 37/4885PPARD 432/4885LPAR3 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.